Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of FY101 injection in Chinese patients with mixed hyperlipidemia
CTR20264122Phase 2Active
- Sponsor
- Beijing Fuyuan Pharmaceutical
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in combined dyslipidaemia comparing FY101 injection with Placebo (2 arms). Started Nov 2026; status: active.
02
Drugs
Zonylia
03
Conditions
combined dyslipidaemia
Beyond the preview
Go deeper on CTR20264122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20264122.